Modeling myeloid malignancies with patient-derived iPSCs

The derivation of human induced pluripotent stem cells (iPSCs) in 2007 ushered in a new era in the modeling of human diseases, including those affecting the hematopoietic system [1-3]. Significant advances over the past decade have enabled investigators to increasingly incorporate iPSC models in their research. iPSCs can empower diverse research studies, ranging from investigations into basic disease mechanisms to more translational applications, such as therapeutic target discovery, drug testing, compound screening, toxicity testing and generation of cells for transplantation [2,4].

Source: Experimental Hematology - November 24, 2018 Category: Hematology Authors: Eirini P. Papapetrou Source Type: research